Literature DB >> 26612323

Utilizing gemstone spectral CT imaging to evaluate the therapeutic efficacy of radiofrequency ablation in lung cancer.

Lei Liu1, Xiuyi Zhi1, Baodong Liu1, Yi Zhang2.   

Abstract

PURPOSE: To evaluate the therapeutic efficacy of radiofrequency ablation (RFA), quantitative water-based, and iodine-based images of gemstone spectral computed tomography (CT) were analyzed. PATIENTS AND METHODS: 30 patients underwent lung RFAs from March 2012 to March 2013. Through enhanced chest scans, we obtained the tumor size values by conventional CT images, and quantitatively analyzed the densities of iodine and water in lung tumors from water-based and iodine-based material decomposition images.
RESULTS: Tumors in 22 cases increased in size after RFA while there was no detectable change in the remaining 8 cases. Through water-based material decomposition images, the water content in the tumors increased from (1014.76 ± 6.83 mg/mL) to (1022.71 ± 10.16 mg/mL) after RFA, and this difference was significant (t = -2.329, p < 0.05). Through iodine-based material decomposition images, the iodine content in the tumors was 2.49 ± 0.74 mg/mL before RFA. The tumors were mostly or completely necrotized after RFA and the iodine content in the area of necrosis reduced to 0.45 ± 0.29 mg/m (t = 11.072, p = 0.000).
CONCLUSION: By comparing the tumor size, water content and iodine content before and after RFA, we can visualize the morphology and metabolic states of the tumors and evaluate the therapeutic efficiency.

Entities:  

Keywords:  Computed tomography; Gemstone spectral imaging; Lung cancer; Radiofrequency ablation

Mesh:

Substances:

Year:  2015        PMID: 26612323     DOI: 10.1007/s11547-015-0602-5

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  14 in total

Review 1.  Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance.

Authors:  S N Goldberg; G S Gazelle; P R Mueller
Journal:  AJR Am J Roentgenol       Date:  2000-02       Impact factor: 3.959

2.  Radiofrequency ablation in a porcine lung model: correlation between CT and histopathologic findings.

Authors:  Akira Yamamoto; Kenji Nakamura; Toshiyuki Matsuoka; Masami Toyoshima; Tomohisa Okuma; Yoshimasa Oyama; Yoshihiro Ikura; Makiko Ueda; Yuichi Inoue
Journal:  AJR Am J Roentgenol       Date:  2005-11       Impact factor: 3.959

Review 3.  Percutaneous radiofrequency ablation of lung tumours: results in the mid-term.

Authors:  Marcello Carlo Ambrogi; Marco Lucchi; Paolo Dini; Franca Melfi; Gabriella Fontanini; Pinuccia Faviana; Olivia Fanucchi; Alfredo Mussi
Journal:  Eur J Cardiothorac Surg       Date:  2006-05-24       Impact factor: 4.191

Review 4.  Dual-energy computed tomography characterization of solitary pulmonary nodules.

Authors:  Eun Jin Chae; Jae-Woo Song; Bernhard Krauss; Koun-Sik Song; Choong Wook Lee; Hyun Joo Lee; Joon Beom Seo
Journal:  J Thorac Imaging       Date:  2010-11       Impact factor: 3.000

Review 5.  Lung cancer and radiofrequency ablation.

Authors:  Steven C Rose; Patricia A Thistlethwaite; Patrick E Sewell; Ralph B Vance
Journal:  J Vasc Interv Radiol       Date:  2006-06       Impact factor: 3.464

6.  Fine-needle aspiration cytologic technique for lung cancer has a high potential of malignant cell spread through the tract.

Authors:  N Sawabata; M Ohta; H Maeda
Journal:  Chest       Date:  2000-10       Impact factor: 9.410

7.  Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates.

Authors:  Hiran C Fernando; Alberto De Hoyos; Rodney J Landreneau; Sebastian Gilbert; William E Gooding; Percival O Buenaventura; Neil A Christie; Chandra Belani; James D Luketich
Journal:  J Thorac Cardiovasc Surg       Date:  2005-03       Impact factor: 5.209

8.  Unresectable pulmonary malignancies: CT-guided percutaneous radiofrequency ablation--preliminary results.

Authors:  Robert D Suh; Amanda B Wallace; Ramon E Sheehan; Stefan B Heinze; Jonathan G Goldin
Journal:  Radiology       Date:  2003-12       Impact factor: 11.105

9.  Preliminary retrospective investigation of FDG-PET/CT timing in follow-up of ablated lung tumor.

Authors:  Fumiyo Higaki; Yoshihiro Okumura; Shuhei Sato; Takao Hiraki; Hideo Gobara; Hidefumi Mimura; Shiro Akaki; Toshihide Tsuda; Susumu Kanazawa
Journal:  Ann Nucl Med       Date:  2008-05-23       Impact factor: 2.668

10.  Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation.

Authors:  Michael D Beland; Elliot J Wasser; William W Mayo-Smith; Damian E Dupuy
Journal:  Radiology       Date:  2010-01       Impact factor: 11.105

View more
  5 in total

1.  Iodine concentration: a new, important characteristic of the spot sign that predicts haematoma expansion.

Authors:  Fan Fu; Shengjun Sun; Liping Liu; Jianying Li; Yaping Su; Yingying Li
Journal:  Eur Radiol       Date:  2018-04-19       Impact factor: 5.315

Review 2.  CT-guided percutaneous laser ablation of metastatic lung cancer: three cases report and literature review.

Authors:  Qiyu Zhao; Guo Tian; Fen Chen; Liyun Zhong; Tian'an Jiang
Journal:  Oncotarget       Date:  2017-01-10

Review 3.  Application of Dual-Energy Spectral Computed Tomography to Thoracic Oncology Imaging.

Authors:  Cherry Kim; Wooil Kim; Sung Joon Park; Young Hen Lee; Sung Ho Hwang; Hwan Seok Yong; Yu Whan Oh; Eun Young Kang; Ki Yeol Lee
Journal:  Korean J Radiol       Date:  2020-07       Impact factor: 3.500

4.  Effects of low-dose energy spectrum scanning combined with adaptive statistical iterative reconstruction on the quality of imaging in Budd-Chiari syndrome.

Authors:  Lei Su; Liyang Chang; Qiang Sun; Lili Hu; Yan Wu; Jianbo Gao
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240

5.  CAMPO Precision128 Max ENERGY Spectrum CT Combined with Multiple Parameters to Evaluate the Benign and Malignant Pleural Effusion.

Authors:  Tianyu Zhang; Cuicui Wu; Zhongtao Li; Yan Ding; Lijuan Wen; Li Wang
Journal:  J Healthc Eng       Date:  2021-02-26       Impact factor: 2.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.